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Studies of inﬂammatory bowel disease (IBD) over many
decades have spanned a wide range of topics from clinical
epidemiology and diagnosis, through dietary and pharma-
cologic therapy and immunologic and biologic etiology, to
pathophysiologic links to malignancy. In this special issue
devoted to IBD, the Guest Editors and one of the authors
have selected a series of seven papers from seven countries
that reﬂect this entire spectrum.
Leading oﬀ with clinical epidemiology, Y. Correa et al.
from the University of Puerto Rico call our attention to the
increasing prevalence of both ulcerative colitis (UC) and
Crohn’s disease (CD) among Hispanics. Particularly note-
worthy is their observation that no particular phenotypic
features consistently distinguish this Puerto Rican cohort
from other white, non-Hispanic populations. Could we take
these ﬁndings to infer that environmental factors are playing
a role in the presentation of IBD that trumps or at least
balances the role of genetics?
From clinical epidemiology in Puerto Rico, we move to
clinical diagnosis in Italy. E. Calabrese et al. at the University
of Rome oﬀer us a review of the utility of contrast-enhanced
ultrasound of the small bowel in the evaluation of patients
with CD. With or without radiation, both CT and magnetic
resonance (MR) enterography are relatively expensive and
labor-intensive, so a lower-cost, more convenient alternative
could be a welcome addition to the armamentarium. Will
contrast-enhanced ultrasound ﬁll this role?
No survey of IBD could be complete without at least
some attention to therapy. G. M. Fung and A. Szilagyi from
McGill University in Montreal caution us against too readily
embracing the fad of carbohydrate withdrawal as dietary
treatment for the symptoms of IBD. They remind us of
the potential importance of carbohydrates as a substrate for
bacterial production of short-chain fatty acids, which are
possibly critical in maintaining anti-inﬂammatory home-
ostasis in the intestinal tract.
Another paper in this special issue shifts from dietary
to pharmacologic therapy. While anti-TNF and anti-integrin
molecules have been occupying most of the spotlight for
IBDtreatmentinthepastdecade,novelapproachestargeting
otherpathwayswillundoubtedlyyetemerge.L.R.Fitzpatrick
from Penn State College of Medicine calls attention to one of
the key alternative pathways in his review of the IL-23/IL-
17 axis. Certainly, it has been a seminal discovery that these
two closely intertwined pathways can both be neutralized
by targeting the common p40 subunit of IL-12 and IL-
23. L. R. Fitzpatrick’s review shows us that several diﬀerent
approaches to targeting this central inﬂammatory pathway,
already usefully exploited in treating psoriasis, might well
p r o v eb e n e ﬁ c i a li nI B Da sw e l l .
The paper by T. L. Holm et al. from Denmark moves
from the bedside to the bench by employing a murine
model of CD. Using the severe combined immunodeﬁciency
disease(SCID)adoptive T-celltransfermodel ofcolitis,these
authors provide an intriguing link to L. R. Fitzpatrick’s
review. It turns out that, among an array of eight diﬀerent
agents tested for prevention or treatment of this form of
experimentalcolitis,onlyanti-IL-12p40andabatacept(cyto-
toxic T-lymphocyte antigen 4 immunoglobulin) induced
remission of established disease. To be sure, this murine
system is far from a perfect model of human IBD, but the
Danish study is certainly a conﬁrmation of the theoretical2 International Journal of Inﬂammation
anti-inﬂammatory potential of targeting the IL-12/23 path-
way.
Thepenultimatepaperconcentratesonthenewestcandi-
date etiology of IBD, namely, intestinal dysbiosis. G. De Her-
tog et al. from Leuven, Belgium, used laser microdissection
of intestinal tissues from four CD patients, six inﬂammatory
disease controls, and three noninﬂamed controls to demon-
strate “signiﬁcant changes of the composition, abundance
and location of the gut microbiome in [Crohn’s] disease.”
This avenue of research is clearly going to be a major focus
over at least the next decade.
Finally, our special issue presents a review of several
inﬂammation-associated colorectal cancer model developed
by T. Tanaka from Japan. He expresses the hope “that use
of these models will advance elucidation of the mechanisms
(methylation and microRNA) of inﬂammation-associated
colorectal carcinogenesis, exploration of its suppression and
mechanisms, and clariﬁcation of the mechanisms of tumor-
promotion activity of DSS [dextran sodium sulfate].”
Wereadilyacknowledgethatthesevenarticlesselectedby
the three indefatigable Guest Editors and me from the many
manuscripts submitted will not provide deﬁnitive answers to
the mysteries of IBD. Nonetheless, this special issue makes
a creditable eﬀort to identify some of the most important
questions.
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